Abstract: The invention is drawn to a new class of isoeicosanoids that have been identified as products of the oxidation of docosahexaenoic acid (DHA). The invention provides compositions and methods related to the new class of molecules.

Abstract: The wobble bearing axle assembly is used for engaging the upper body of a person for use in human powered vehicles and exercise equipment. The wobble bearing assembly converts linear input force derived by the operator into rotational force, which is directed toward the forward propulsion of a wheel. The wobble bearing axle assembly comprises a wobble bearing, a wobble axle, at least two engagement members a first arm and a second arm. The wobble bearing is disposed upon the oblique retainer of the wobble axle. The oblique retainer of the wobble axle is angled offset from the axis of the wobble axle Y. The engaging members are rotatably affixed with the first and second arms through pins which is longitudinally disposed through complementary orifices through the first and second arms and the engaging members respectively. In some preferred embodiments additional bearings are engaged with the pedals powered by the legs of the operator.

Abstract: The present invention relates to a prostaglandin D2 metabolite, derivatives thereof, compositions comprising the metabolite, and an antibody that specially binds to the metabolite. Methods of use are also provided.

Abstract: A Wave Generating System for Converting Ocean Waves into Usable Energy includes a Base, a Polyp, and a Stem. The Polyp is connected to the Stem. The Stem is connected to the Base. In some preferred embodiments the Base may require a mooring design to counter both the upward force and a tendency to tip, which can release gas. The Base is comprised of a plurality of first chamber, a second chamber, and a third chamber. In some preferred embodiments, the first chamber may be used to store Hydrogen, the second chamber may be used to store Oxygen, and the third chamber may be used to store breathable air for operators. The third chamber is also used for the purpose of imparting buoyancy to the Base.

Abstract: There are provided nutritional compositions comprising a source of tryptophan and which nutritional compositions further comprise one or more components selected from the group consisting of: a caseinate; magnesium lactate; magnesium gluconate; zinc lactate; and zinc gluconate. Also provided are beverages, food products and methods of consumption.

Abstract: There is provided a method of manufacturing a nutritional composition comprising carbohydrate in an amount of at least 250 g l?1 of composition. The method comprises the steps of: (i) combining a first gelling agent and water; (ii) heating the mixture produced in step (i) to a temperature of between 60° C. and 100° C.; (iii) combining a second gelling agent with the heated mixture of step (ii) with mixing; and (iv) maintaining the mixture produced in step (iii) at a temperature of between 70° C. and 100° C. for between 10 and 120 minutes; with a carbohydrate component being combined with the mixture during one or more of said steps. Also provided is a nutritional composition.

Abstract: The disclosure describes morphinan compounds and methods for their synthesis. Preferred methods according to the disclosure allow for large-scale preparation of diastereomerically enriched morphinans. Preferred methods according to the disclosure may also allow for the preparation of diastereomerically enriched morphinans using less time, and/or using fewer reaction steps, and/or providing better yield than previously used methods for preparing morphinans. The methods disclosed herein find utility in synthetic organic chemistry as well as medicinal chemistry.

Abstract: The present invention relates to a method of producing rough strains of a bacterium, such as Mycobacterium obuense, said method comprising exposing said bacterium to a sulfone and/or sulfonamide (such as 4,4?-Diaminodiphenyl sulfone or an analogue thereof). A rough strain of Mycobacterium obuense producible by said method and uses thereof. In particular, uses of a rough strain of Mycobacterium obuense deposited under the Budapest Treaty of NCTC with the accession number NCTC 13365.

Abstract: A method is provided for treating a drug-dependent individual so as to effect withdrawal from a drug of abuse, e.g., an opiate such as heroin or oxycodone, a stimulant such as cocaine, or alcohol. The method involves substitution therapy wherein a substantially nonaddicting normorphine or norcodeine derivative is substituted for the drug of abuse. The active agent has the structure of formula (I) wherein: R is H, alkyl, or acyl; X is CH(OR?) or C?O, wherein R? is H or acyl; ? is an optional double bond, with the proviso that when ? is present, then X is necessarily CH(OH), or an acid addition salt thereof, wherein preferred such agents are in a stereoisomerically pure form that corresponds to that of N-[(1R)-1-cyclopropylethyl]-normorphine (1) which melts at approximately 188° C.-189° C.

Abstract: The present invention provides a method for testing an agent for its ability to inhibit binding between fibroblast growth factor (FGF) and heparan sulfate, comprising the steps of: interacting in solution immobilized FGF on a solid support with the agent and labeled heparan sulfate, and detecting the presence or absence of label in the solution remote from the solid support.

Abstract: An apparatus for draining condensate accumulated by an air handling unit element, the element presenting a footprint area, includes: a substantially unitary plurality of surfaces oriented between a first level and a second level and bounded by a peripheral wall. The first level is generally higher than the second level in an installed orientation. A first surface is situated substantially at the first level and is generally horizontal and presents a generally planar expanse generally coextensive with the footprint area in the installed orientation. A second surface generally extends from the second level at a first end of the apparatus to the first level at two loci separated by the first surface at a second end of the apparatus opposite the first end to orient the first surface in a generally nested relationship with respect to the second surface. At least one third surface joins the first and second surfaces.

Abstract: Use of a composition comprising a whole cell of a bacterium from a genus of aerobic organisms in the order of Actinomycetales in the manufacture of a medicament for modulating the immune response of a recipient wherein said composition is administered to a subject and said recipient is exposed to a bodily of said subject whilst said recipient is an infant. Preferably the medicament is used for the prevention and/or treatment of one or more of: an infection, an allergy, an autoimmune-based disease and a neoplasm in said recipient.

Abstract: An immune modulator composition and/or pharmaceutical composition comprising a whole cell of a bacterium from the genera Rhodococcus, Gordonia, Nocardia, Dietzia, Tsukamurella and Nocardioides, wherein said immune modulator composition in use modifies a cellular immune response.

Abstract: Use of whole cells of bacteria from the genera of aerobic organisms in the order of Actinomycetales in the manufacture of a medicament for the treatment or prevention of stress-induced pulmonary haemorrhage (SIPH), preferably exercise induced pulmonary haemorrhage (EIPH), and methods of treating or preventing SIPH, preferably EIPH, in a subject by administering an effective amount of a composition comprising a whole cell of a bacterium from a genera of aerobic organisms in the order of Actinomycetales to said subject. Preferably the aerobic organism is from one or more of the following genera for example: Tsukamurella, Rhodococcus, Gordonia, Nocardia, Dietzia and Mycobacterium.

Abstract: A multi-channel flow cell can allow for reduced cross-contamination in sample loading and the ability to observe activity within the flow cell once the channels are loaded. A multi-channel flow cell includes a plurality of independently-addressable channels sandwiched between a two substrates. Each of the channels can be coated with a layer that facilitates support-binding of an analyte. Each of the channels terminates on one end in an inlet and on the other end in an outlet. A loading block having inlet ports that match the inlets of the channels can be mated to the inlets of the channels, and an outlet block can be mated to the outlets of the channels. Analytes can be introduced into the channels via the inlet ports of the loading block and are pulled through the channels by capillary action or by vacuum.

Abstract: Use of whole cells of bacteria from the genera of aerobic organisms in the order of Actinomycetales in the manufacture of a medicament for the treatment or prevention of Type II diabetes and/or obesity and methods of treating or preventing Type II diabetes and/or obesity in a subject by administering an effective amount of a composition comprising a whole cell of a bacterium from a genera of aerobic organisms in the order of Actinomycetales to said subject. Preferably the bacteria is from one or more of the following genera for example: Gordonia, Rhodococcus, Tsukamurella, Nocardia, Dietzia and Mycobacterium.

Abstract: This invention relates to a method for treating or preventing (including immunising against) post-wearing multisystemic wasting syndrome (PMWS) and/or porcine dermatitis and nephropathy syndrome (PDNS) in a subject comprising administering an effective amount of a pharmaceutical composition or immune modulator composition comprising a whole cell of a bacterium from one or more of the genera Rhodococcus, Gordonia, Nocardia, Dietzia, Tsukamurella and Nocardioides, to said subject. In addition the method relates to the use of an immune modulator composition or a pharmaceutical composition comprising a whole cell of a bacterium from the genera Rhodococcus, Gordonia, Nocardia, Dietzia, Tsukamurella and Nocardioides, in the manufacture of a medicament for the treatment or prevention of post-wearing multisystemic wasting syndrome (PMWS) and/or porcine dermatitis and nephropathy syndrome (PDNS).

Abstract: A multi-channel flow cell can allow for reduced cross-contamination in sample loading and the ability to observe activity within the flow cell once the channels are loaded. A multi-channel flow cell includes a plurality of independently-addressable channels sandwiched between a two substrates. Each of the channels can be coated with a layer that facilitates support-binding of an analyte. Each of the channels terminates on one end in an inlet and on the other end in an outlet. A loading block having inlet ports that match the inlets of the channels can be mated to the inlets of the channels, and an outlet block can be mated to the outlets of the channels. Analytes can be introduced into the channels via the inlet ports of the loading block and are pulled through the channels by capillary action or by vacuum. Once analyte has been introduced into each of the channels, the loading and outlet blocks can be removed and the device turned over.

Abstract: A apparatus and method for loading a sample into a microfluidic flow cell allows for more precise loading, reduced cross-contamination, and more efficient use of samples to be analyzed. The system for loading a sample into a flow cell includes a flow cell defining a plurality of individually isolated channels through which fluid can flow. The flow cell also defines an inlet port and an outlet port for each of the channels. The system also includes a base that defines a chamber for receiving the flow cell, a cover pivotally attached to the base, and a passive vacuum source for pulling a volume through the flow cell. The method of loading a sample includes inserting the flow cell into the sample loading apparatus, placing a sample in at least one of the wells of the loading block, activating a vacuum source fluidly coupled to the outlet ports to pull the sample into the channel, and optionally aspirating the unused sample from the well.

Abstract: Use of an immune modulator composition and/or pharmaceutical composition comprising a whole cell of a bacterium from the genera Rhodococcus, Gordonia, Nocardia, Dietzia, Tsukamurella and Nocardioides, for use in the manufacture of a medicament for the treatment of an autoimmune disease or autoimmune disorder, including certain vascular disorders.